NEKOTORYE OSOBENNOSTI LEChENIYa BISFOSFONATAMI INVOLYuTIVNOGO OSTEOPOROZA U LYuDEY STARShEGO VOZRASTA


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The review is devoted to the approaches to diagnosis, treatment and prevention of osteoporosis. The main attention is paid to the features of the use of zoledronic acid. Data from randomized clinical trials allows to conclude the following: therapy with zoledronic acid can reduce the risk of clinical vertebral and non-vertebral fractures and recurrent hip fractures. Use of the drug in postmenopausal women with low bone mineral density allows to reach a preventive effect. The form of the drug for intravenous administration contributes to the organization of strict control over the amount of therapy and its effectiveness, that allows to consider this medication as a priority drug in the presence of the factors contributing to poor patient compliance.

Full Text

Restricted Access

About the authors

E. G Zotkin

Email: ezotkin@mail.ru

References

  1. Социально-демографический портрет России: по итогам Всероссийской переписи населения 2010 г. / Фед. служба госстатистики М., 2012. 183 с.
  2. Сафарова Г.Л. Старение населения Санкт-Петербурга: современное состояние и среднесрочные перспективы. Успехи геронтологии. 2002;10:18-28.
  3. National Osteoporosis Foundation. Fast facts. Available at: www.nof.org/node/40. Accessed September 6, 2011.
  4. Burge R., Dawson-Hughes B., Solomon D.H., et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J. Bone Miner. Res. 2007;22:465-75.
  5. Klotzbuecher C.M., Ross P.D., Landsman P.B., et al. Patients with Prior Fractures Have an Increased Risk of Future Fractures: a Summary of the Literature and Statistical Synthesis. J. Bone Miner. Res. 2000;4:721-39.
  6. Laliberte M.C., Perreault S., Jouini G., et al. Effectiveness of interventions to improve the detection and treatment of osteoporosis in primary care settings: a systematic review and metaanalysis. Osteoporos. Int. 2011;11:2743-68.
  7. Genant H.K., Cooper C., Poor G., et al. Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos. Int. 1999;4:259-64.
  8. Kanis J.A., Johnell O., Oden A., et al. FRAXTM and the assessment of fracture probability in men and women from the UK. Osteoporos. Int. 2008;19(4):385-97.
  9. Reginster J.Y. Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. Drugs. 2011;11:65-78.
  10. Crandall C.C., Newberry S.J., Gellad W.G., et al. Comparative effectiveness of trearmment to prevent fractures in men and women with low bone density or osteoporosis - update of a 2007 report. Available at: http://www.effectivehealth-care.ahrq.gov/ Accessed May 8, 2012.
  11. Harris S.T., Watts N.B., Genant H.K., et al. for the VERT Study Group. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA. 1999;282:1344-52.
  12. McClung M.R., Geusens P., Miller P.D., et al., for the Hip Intervention Program (HIP) Study Group. Effect of risedronate on the risk of hip fracture in elderly women. N. Engl. J. Med. 2001; 344:333-40.
  13. McClung M.R., Geussens P., Miller P.D., et al. Effect of risedronate on the risk of hip fracture in elderly women. N. Engl. J. Med. 2001: 344:333-40.
  14. Cummings S.R., Black D.M., Thompson D.E., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. Results from the Fracture Intervention Trial. JAMA. 1998;280:2077-82.
  15. Boonen S., Marin F., Mellstrom D., et al. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. J. Am. Geriatr. Soc. 2006;54:782-89.
  16. Seeman E., Vellas B., Benhamou C., et al. Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older. J. Bone Miner. Res. 2006;21:1113-20.
  17. Cauley J.A., Robbins J., Chen Z., et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA. 2003;290:1729-38.
  18. Dunford J.E., Thompson K., Coxon F.P., et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol. Exp. Ther. 2001;2:235-42.
  19. Skerjanec A., Berenson J., Hsu C., et al. The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. J. Clin. Pharmacol. 2003.;2:154-62.
  20. Black D.M., Delmas P.D., Eastell R., et al. Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. N. Engl. J. Med. 2007;356:1809-22.
  21. Recker R.R., Delmas P.D., Halse J., et al. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J. Bone Miner. Res. 2008;1:6-16.
  22. Gamsjaeger S., Buchinger B., Zwettler E., et al. Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly zoledronic acid. J. Bone Miner. Res. 2010;25:292-97.
  23. McClung M., Miller P., Recknor C., et al. Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass. Obstet. Gynecol. 2009;114:999-1007.
  24. Lyles K.W., Colyn-Emeric C.S., Magaziner J.S., et al. Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture. N. Engl. J. Med. 2007;357:1799-809.
  25. Eriksen E.F., Lyles K.W., Colen-Emeric C.S., et al. Antifracture efficacy and reduction of mortal ity in relation to timing of the first dose of zoledronic acid after hip fracture. J. Bone Miner. Res. 2009;7:1308-13.
  26. Reid D.M., Devogelaer J.P., Saag K., et al. HORIZON investigators. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): A multicenter, double-blind, double-dummy, randomized controlled trial. Lancet. 2009;373:1253-63.
  27. Roux C., Reid D.M., Devogelaer J.P., Saag K. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis. Osteoporos. Int. 2012;3: 1083-90.
  28. Orwoll E.S., Miller P.D., Adachi J.D., et al. Efficacy and safety of a once-yearly i.v. infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J. Bone Miner. Res. 2010;10:2239-50.
  29. Eastell R., Black D.M., Boonen S., et al. Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density. J. Clin. Endocrinol. Metab. 2009;9:3215-25.
  30. Boonen S., Black D.M., Colon-Emeric C.S., et al. Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J. Am. Geriatr. Soc. 2010;2:292-99.
  31. Cosman F., Eriksen E.F., Recknor C. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J. Bone Miner. Res. 2009; 26:503-11.
  32. Curtis J.R., Cai Q., Wade S.W., Stolshek B.S. Osteoporosis medication adherence: physician perceptions vs. patients' utilization. Bone. 2013;11:1-6.
  33. McClung M., Recker R., Miller P., et al. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone. 2007;1:122-28.
  34. Camm J.A. Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis. Clin. Ther. 2010;3:426-36.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies